News

Applied Clinical Trials Online17h
MariTide Shows Up to 20% Weight Loss in Phase II Trial for Obesity, Type 2 Diabetes
In a Phase II trial, Amgen’s investigational therapy MariTide (maridebart cafraglutide) delivered significant, sustained ...
Pharmabiz10m
Amgen announces phase 2 obesity study results of MariTide; presents at 85th American Diabetes Association Scientific Sessions
Thousand Oaks, California Wednesday, June 25, 2025, 13:00 Hrs [IST] ...
Analyst Views Mixed As Amgen's Weight Loss/Diabetes Drug MariTide Shows Promise But Has Dose Issues
Amgen's MariTide showed strong weight loss and metabolic gains in Phase 2, with no new safety signals as Phase 3 trials begin in obesity and T2D.
Fierce Biotech17h
Amgen rolls out phase 3 dosing plan for lead obesity candidate after midstage trial sees high discontinuation, vomiting rates
While Amgen’s monthly obesity candidate MariTide helped patients lose significant amounts of weight in a phase 2 study, ...
BioPharma Dive15h
New Amgen obesity drug data disappoint Wall Street
Full Phase 2 study results showed side effects that led people to stop treatment with MariTide, as well as weight loss ...
STAT1d
Amgen’s obesity drug led to high discontinuation rates in mid-stage trial, as company plans to adjust dosing
Amgen’s monthly obesity candidate led to substantial weight loss but a high rate of side effects and discontinuations in a ...
Devdiscourse1d
Amgen's MariTide: Promising Weight Loss with Milder Side Effects
Amgen's experimental obesity drug MariTide showed promising weight loss results with fewer side effects, according to a ...
Amgen experimental weight-loss drug needs lower dose to limit side effects
Amgen's long-acting experimental obesity drug MariTide needs to be given at a low starting dose to limit side effects like ...
Lilly, Novo, and Amgen set for key obesity trial readouts at upcoming ADA event
Novo Nordisk (NVO), and Amgen (NASDAQ:AMGN) are scheduled to present major clinical trial readouts at the American Diabetes ...